Ascentage Pharma Group International
NASDAQ:AAPGBiotechnology
+$0.31 today
- Market cap
- $1.21B
- Beta
- 0.65
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$13.29
Volume 0.00M
Average 0.01M
AAPG Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Ascentage Pharma Group InternationalNASDAQ: AAPG
Accounts Receivables · Q4 FY2025 · quarter ended Dec 2025
Accounts receivables outflow shrinks to CN¥0
Q4 FY2025 accounts receivables was CN¥0, compared with CN¥62.75M a year earlier. Over 3 fiscal years it compounded at +659.2% a year.
Context
- Accounts receivables amounted to 30.4% of revenue in FY2025, up 24.0 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
CNY · from the cash flow
- Latest · FY2025
- (169.8M) CNY
- Year-over-year change
- -370.6%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (169.8M) | -370.6% |
| FY2024 | 2024-12-31 | 62.75M | +168.6% |
| FY2023 | 2023-12-31 | (91.54M) | -23492.0% |
| FY2022 | 2022-12-31 | (388K) | +99.3% |
| FY2021 | 2021-12-31 | (53.97M) | — |
Accounts Receivables vs competitors
How AAPG compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -370.6% is the 5th highest of 6, against a peer median of -7.6%.
- Accounts receivables amounts to 30.4% of revenue for AAPG, versus a peer median of 5.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | FY2025 | CN¥169.8M CNY | -370.6% | +659.2% | 30.4% |
| LTM Jun 2026 | $26.3M USD | +212.9% | — | 5.8% | |
| LTM Mar 2026 | $10.16M USD | -39169.2% | — | 20.5% | |
| LTM Jun 2026 | $9.62M USD | +260.7% | — | 5.7% | |
| LTM Mar 2026 | $5.15M USD | -7.6% | -45.1% | 14.8% | |
| LTM Sep 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| LTM Aug 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Jun 2024 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding AAPG) | — | -7.6% | -45.1% | 5.7% | |
Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (832.25M) | (887.17M) | (932.86M) | (395.26M) | (1.24B) |
| Depreciation & Amortization | 28.33M | 62.92M | 93.2M | 93.17M | 86.48M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 46.97M | 22.11M | 31.5M | 20.92M | 20.87M |
| Change in Working Capital | (74.91M) | 104.41M | (9.15M) | 110.97M | (143.5M) |
| Accounts Receivables | (53.97M) | (388K) | (91.54M) | 62.75M | (169.8M) |
| Inventory | (3.93M) | (5.52M) | (6.72M) | 9.57M | (26.2M) |
| Accounts Payables | 0 | 24.7M | (23.11M) | 19.52M | 14.77M |
| Other Working Capital | (17.01M) | 85.62M | 112.22M | 19.13M | 37.72M |
| Other Non-Cash Items | 227.18M | 43.82M | 91.23M | 58.84M | 98.07M |
| Operating Cash Flow | (604.68M) | (653.92M) | (726.08M) | (111.36M) | (1.17B) |
| Capital Expenditures | (436.63M) | (236.96M) | (56.84M) | (24.29M) | (27.57M) |
| Acquisitions (Net) | (36.2M) | (20M) | (20M) | (25.52M) | (43.34M) |
| Purchases of Investments | (1.78B) | (130M) | 0 | (312.23M) | (929.14M) |
| Sales of Investments | 1.79B | 0 | 0 | 0 | 0 |
| Other Investing Activities | (879K) | (31.32M) | 88.03M | (312.23M) | 0 |
| Investing Cash Flow | (466.52M) | (384.61M) | 21.92M | (362.04M) | (1B) |
| Debt Repayment | 548.59M | 695.87M | (13.36M) | (145.34M) | 307.26M |
| Common Stock Issued | 1.3B | 0 | 470.08M | 533.94M | 2.3B |
| Common Stock Repurchased | (25.87M) | (26.78M) | (5.92M) | 0 | (9.04M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (41.97M) | (49.83M) | (82.05M) | (73.83M) | (63.04M) |
| Financing Cash Flow | 1.78B | 619.27M | 368.75M | 314.77M | 2.54B |
| Effect of Forex Changes | (23.28M) | 58.01M | 27.81M | 13.68M | (63.24M) |
| Net Change in Cash | 686.91M | (361.25M) | (307.59M) | (144.95M) | 302.68M |
| Free Cash Flow | (1.04B) | (890.88M) | (782.92M) | (135.65M) | (1.2B) |
Ascentage Pharma Group International
NASDAQ:AAPG
Intrinsic Alpha fair value
Locked
Current Price
$13.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.